Published in J Natl Compr Canc Netw on February 01, 2012
Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol (2014) 2.57
The utility of nodule volume in the context of malignancy prediction for small pulmonary nodules. Chest (2014) 2.30
Low-Dose CT Lung Cancer Screening Practices and Attitudes among Primary Care Providers at an Academic Medical Center. Cancer Epidemiol Biomarkers Prev (2015) 1.52
Screening for lung cancer with low-dose computed tomography: a review of current status. J Thorac Dis (2013) 1.01
Attitudes and Beliefs of Primary Care Providers in New Mexico About Lung Cancer Screening Using Low-Dose Computed Tomography. Prev Chronic Dis (2015) 0.96
Lung cancer screening: review and performance comparison under different risk scenarios. Lung (2013) 0.94
Findings in asymptomatic HIV-infected patients undergoing chest computed tomography testing: implications for lung cancer screening. AIDS (2014) 0.92
Lung cancer screening with low-dose computed tomography for primary care providers. Prim Care (2014) 0.90
Pro-surfactant protein B as a biomarker for lung cancer prediction. J Clin Oncol (2013) 0.88
Predictive biomarkers in precision medicine and drug development against lung cancer. Chin J Cancer (2015) 0.87
Lung Malignancies in HIV Infection. Semin Respir Crit Care Med (2016) 0.85
Insulin-like growth factor binding protein-2 level is increased in blood of lung cancer patients and associated with poor survival. PLoS One (2013) 0.84
Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry. Metabolites (2015) 0.83
Geographic variation in radiologist capacity and widespread implementation of lung cancer CT screening. J Med Screen (2014) 0.82
Evidence based imaging strategies for solitary pulmonary nodule. J Thorac Dis (2014) 0.81
Advanced imaging (positron emission tomography and magnetic resonance imaging) and image-guided biopsy in initial staging and monitoring of therapy of lung cancer. Cancer J (2013) 0.81
Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada. J Thorac Oncol (2014) 0.81
Moving beyond the national lung screening trial: discussing strategies for implementation of lung cancer screening programs. Oncologist (2013) 0.80
What is quality, and can we define it in lung cancer?-the case for quality improvement. Transl Lung Cancer Res (2015) 0.79
Results of the national lung cancer screening trial: where are we now? Thorac Surg Clin (2015) 0.77
National comprehensive cancer network. J Natl Compr Canc Netw (2013) 0.77
Can quantifying free-circulating DNA in plasma be used to identify subjects with high-grade pre-invasive endobronchial lesions? Oncol Lett (2013) 0.76
Predicted for greatness: 1994 molecule of the year--the DNA repair enzyme. Cancer Prev Res (Phila) (2014) 0.76
Computed tomography surveillance scanning after lung cancer surgery: mathematical optimization of scanning interval based on tumour biology. Interact Cardiovasc Thorac Surg (2013) 0.75
Risk factors assessment and risk prediction models in lung cancer screening candidates. Ann Transl Med (2016) 0.75
Cost-effectiveness analysis of lung cancer screening with low-dose computerised tomography of the chest in Poland. Contemp Oncol (Pozn) (2015) 0.75
Is chest X-ray screening for lung cancer in smokers cost-effective? Evidence from a population-based study in Italy. Cost Eff Resour Alloc (2015) 0.75
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program. J Natl Cancer Inst (2010) 4.04
Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis. J Clin Oncol (2012) 2.72
Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer (2006) 2.42
A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genet Med (2010) 2.40
Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst (2014) 2.30
Health care costs among renal cancer patients using pazopanib and sunitinib. J Manag Care Spec Pharm (2015) 2.15
Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2013) 2.11
Stakeholder participation in comparative effectiveness research: defining a framework for effective engagement. J Comp Eff Res (2012) 1.91
Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study. Ann Intern Med (2014) 1.87
Breast cancer in limited-resource countries: an overview of the Breast Health Global Initiative 2005 guidelines. Breast J (2006) 1.85
Sex, depression, and risk of hospitalization and mortality in chronic obstructive pulmonary disease. Arch Intern Med (2007) 1.77
Multi-modality mediastinal staging for lung cancer among medicare beneficiaries. J Thorac Oncol (2009) 1.76
Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology (2004) 1.71
Value-of-information analysis within a stakeholder-driven research prioritization process in a US setting: an application in cancer genomics. Med Decis Making (2013) 1.70
The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med (2007) 1.68
Design, implementation, and first-year outcomes of a value-based drug formulary. J Manag Care Spec Pharm (2015) 1.67
The costs of treating breast cancer in the US: a synthesis of published evidence. Pharmacoeconomics (2009) 1.56
Trends in treatment costs for localized prostate cancer: the healthy screenee effect. Med Care (2007) 1.38
Breast cancer in limited-resource countries: health care systems and public policy. Breast J (2006) 1.35
Stakeholder assessment of the evidence for cancer genomic tests: insights from three case studies. Genet Med (2012) 1.32
Costs and survival of patients with colorectal cancer in a health maintenance organization and a preferred provider organization. Med Care (2005) 1.31
Economic burden for informal caregivers of lung and colorectal cancer patients. Oncologist (2010) 1.30
Quantifying losses to the donated blood supply due to donor deferral and miscollection. Transfusion (2004) 1.29
Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet Med (2005) 1.27
Preliminary treatment considerations among men with newly diagnosed prostate cancer. Am J Manag Care (2010) 1.24
End-of-life care in the intensive care unit: can we simultaneously increase quality and reduce costs? Am J Respir Crit Care Med (2012) 1.20
Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol (2009) 1.17
Measuring costs: administrative claims data, clinical trials, and beyond. Med Care (2002) 1.16
Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med (2005) 1.16
The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health (2008) 1.16
Physiologic variables and functional status independently predict COPD hospitalizations and emergency department visits in patients with severe COPD. COPD (2007) 1.12
Does adherence make a difference? Results from a community-based aquatic exercise program. Nurs Res (2002) 1.10
Economic analyses of human genetics services: a systematic review. Genet Med (2005) 1.10
New-onset treatment-dependent diabetes mellitus and hyperlipidemia associated with atypical antipsychotic use in older adults without schizophrenia or bipolar disorder. J Am Geriatr Soc (2012) 1.08
Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer (2008) 1.06
Comparative effectiveness of combined digital mammography and tomosynthesis screening for women with dense breasts. Radiology (2014) 1.05
Health technology assessment in health-care decisions in the United States. Value Health (2009) 1.03
A multifaceted intervention in support of diabetes treatment guidelines: a cont trial. Diabetes Res Clin Pract (2002) 1.02
Referral and treatment patterns among patients with stages III and IV non-small-cell lung cancer. J Oncol Pract (2013) 1.01
Costs of pulmonary rehabilitation and predictors of adherence in the National Emphysema Treatment Trial. COPD (2008) 1.00
Stakeholder perspectives on a risk-benefit framework for genetic testing. Public Health Genomics (2010) 0.98
Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects. J Natl Cancer Inst (2013) 0.98
Provider and partner interactions in the treatment decision-making process for newly diagnosed localized prostate cancer. BJU Int (2011) 0.98
The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007). Contemp Clin Trials (2012) 0.97
Improving early cycle economic evaluation of diagnostic technologies. Expert Rev Pharmacoecon Outcomes Res (2014) 0.96
An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis. J Gastroenterol Hepatol (2009) 0.95
Community blood supply model: development of a new model to assess the safety, sufficiency, and cost of the blood supply. Med Decis Making (2005) 0.94
Advanced diagnostic breast cancer imaging: variation and patterns of care in Washington state. J Oncol Pract (2013) 0.93
Economic analyses and clinical practice guidelines: why not a match made in heaven? J Gen Intern Med (2002) 0.93
Is distance to provider a barrier to care for medicaid patients with breast, colorectal, or lung cancer? J Rural Health (2011) 0.93
Increased risk of adenomas in individuals with a family history of colorectal cancer: results of a meta-analysis. Cancer Causes Control (2010) 0.92
Costs and outcomes evaluation of patient navigation after abnormal cancer screening: evidence from the Patient Navigation Research Program. Cancer (2013) 0.92
Genetic services for familial cancer patients: a follow-up survey of National Cancer Institute Cancer Centers. J Clin Oncol (2005) 0.92
Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer. Drugs (2008) 0.92
Clinical use of medical devices in the 'Bermuda Triangle'. Health Aff (Millwood) (2004) 0.92
Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. Am J Manag Care (2004) 0.91
Home telemedicine for paediatric palliative care. Stud Health Technol Inform (2010) 0.90
Preference values associated with stage III colon cancer and adjuvant chemotherapy. Qual Life Res (2010) 0.89
Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy. Epilepsia (2011) 0.88
Completion of radiotherapy for local and regional head and neck cancer in medicare. Arch Otolaryngol Head Neck Surg (2009) 0.86
Systematic review of comparative effectiveness data for oncology orphan drugs. Am J Manag Care (2012) 0.86
The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma. Cancer (2005) 0.86
Lung cancer histology, stage, treatment, and survival in American Indians and Alaska Natives and whites. Cancer (2010) 0.85
Effect of radiotherapy interruptions on survival in medicare enrollees with local and regional head-and-neck cancer. Int J Radiat Oncol Biol Phys (2010) 0.85
Facilitating comparative effectiveness research in cancer genomics: evaluating stakeholder perceptions of the engagement process. J Comp Eff Res (2012) 0.84
Screening for the Lynch syndrome. N Engl J Med (2005) 0.83
The feasibility of a community-based mobile telehealth screening service for Aboriginal and Torres Strait Islander children in Australia. Telemed J E Health (2010) 0.83
Evidence-based management: using serial firm trials to improve diabetes care quality. Jt Comm J Qual Improv (2002) 0.83
Complementary and alternative medicine use among newly diagnosed prostate cancer patients. Support Care Cancer (2010) 0.82
Promoting quality and evidence-based care in early-stage breast cancer follow-up. J Natl Cancer Inst (2014) 0.82
Cost-effectiveness of a 14-gene risk score assay to target adjuvant chemotherapy in early stage non-squamous non-small cell lung cancer. Oncologist (2014) 0.82
Comparing hospital-based resource utilization and costs for prostate cancer patients with and without bone metastases. Appl Health Econ Health Policy (2014) 0.82
Patient recruitment methods to evaluate treatment decision making for localized prostate cancer. Am J Clin Oncol (2010) 0.82
Considering racial and ethnic preferences in communication and interactions among the patient, family member, and physician following diagnosis of localized prostate cancer: study of a US population. Int J Gen Med (2011) 0.81
A guideline for the use of pharmacoeconomic models of diabetes treatment in the US managed-care environment. Pharmacoeconomics (2002) 0.81
The outcomes of the cancer outcomes research symposium: a commentary. Med Care (2002) 0.81
A pilot study of the effectiveness of home teleconsultations in paediatric palliative care. J Telemed Telecare (2012) 0.81
Access to the Indian health service care system is not associated with early enrollment in medicaid for American Indian and Alaska Natives with cancer. Cancer Epidemiol Biomarkers Prev (2013) 0.81
Moving beyond the national lung screening trial: discussing strategies for implementation of lung cancer screening programs. Oncologist (2013) 0.80
Health care use and primary prophylaxis with colony-stimulating factors. Value Health (2011) 0.80
How should we value lives lost to cancer? J Natl Cancer Inst (2008) 0.79
Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis. J Cancer Res Clin Oncol (2009) 0.79
Aspirin, clopidogrel, or both for secondary prevention of coronary disease. N Engl J Med (2003) 0.79
Association of Preexisting Symptoms with Treatment Decisions among Newly Diagnosed Prostate Cancer Patients. Patient (2008) 0.79
Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspective. Support Care Cancer (2013) 0.79
Body mass index and cancer screening in older American Indian and Alaska Native men. J Rural Health (2009) 0.79
Cost-effectiveness of prostate cancer chemoprevention among high-risk men. Expert Rev Pharmacoecon Outcomes Res (2010) 0.78
Lung cancer screening with low-dose computed tomography. J Natl Compr Canc Netw (2013) 0.78
Getting our priorities straight: a novel framework for stakeholder-informed prioritization of cancer genomics research. Genet Med (2012) 0.78
Systemic therapy for colorectal cancer: patterns of chemotherapy and biologic therapy use in nationally representative US claims database. BioDrugs (2014) 0.78
The costs and potential savings of telemedicine for acute care neonatal consultation: preliminary findings. J Telemed Telecare (2012) 0.78
The forest and the trees: the human costs of cancer. J Natl Cancer Inst (2007) 0.77
Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer. J Comp Eff Res (2014) 0.77
What Happens When Imatinib Goes Generic? J Natl Compr Canc Netw (2016) 0.77
Is a comparative clinical trial for breast cancer tumor markers to monitor disease recurrence warranted? A value of information analysis. J Comp Eff Res (2013) 0.77